ArticlePloS one2024

Economic and budgetary impact evaluation of isavuconazole (Cresemba®) versus voriconazole (Vfend®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system.

Gisele Lemes Veiga Araujo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.